SM
ALDX icon

Sabby Management’s Aldeyra Therapeutics ALDX Stock Holding History

Sabby Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-97,704
Closed -$454K – 168
2017
Q2 		$454K Sell
97,704
-81,923
-46% -$377K 0.03% 146
2017
Q1 		$898K Buy
+179,627
New +$925K 0.05% 137
2016
Q2 		– Sell
-41,096
Closed -$172K – 290
2016
Q1 		$172K Sell
41,096
-27,603
-40% -$133K 0.01% 262
2015
Q4 		$466K Sell
68,699
-66,298
-49% -$446K 0.03% 241
2015
Q3 		$787K Sell
134,997
-131,956
-49% -$1.03M 0.03% 264
2015
Q2 		$2.07M Buy
+266,953
New +$2.3M 0.08% 161

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Sabby Management's ALDX Position: Q3 2017 in Review

Sabby Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2017, closing a stake of 97,704 shares — an estimated $454K sold.

Sabby Management first reported a position in ALDX in Q2 2015 and held it in 6 quarters. The position peaked at $2.07M in Q2 2015. 35 funds tracked by Wall St. Rank hold ALDX as of Q3 2017.

  • Sabby Management reported no remaining Aldeyra Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 97,704 Aldeyra Therapeutics shares in Q3 2017, an estimated $454K.
  • Sabby Management first reported a position in Aldeyra Therapeutics in Q2 2015 and held it in 6 quarters.
  • Sabby Management's Aldeyra Therapeutics position peaked at $2.07M in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.